<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00917839</url>
  </required_header>
  <id_info>
    <org_study_id>LT.01</org_study_id>
    <nct_id>NCT00917839</nct_id>
  </id_info>
  <brief_title>The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>Randomized, Placebo-Controlled Phase II Monocentric Trial for the Neuroprotective Effect of Lamotrigine Plus Interferon Beta 1a 30mcg Once Weekly Intramuscular in Patients With Relapsing-Remitting Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the neuroprotective effect of lamotrigine in the
      combination of interferon beta 1a once weekly intramuscular in patients with
      relapsing-remitting multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>N-Acetyl-Aspartate / creatine - quotient in normal appearing white matter by MR-spectroscopy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of lamotrigine in combination with interferon beta 1a (30 mcg) once weekly intramuscular.</measure>
    <time_frame>6 months, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded disability status score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-Acetyl-Aspartate / creatine - quotient in normal appearing white matter by MR-spectroscopy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>lamotrigine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 weeks initial phase with increasing dose beginning with 25 mg oral 12 months treatment phase with fixed dose of 100 mg oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300mg Mannitol with 2% Aerosil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamotrigine</intervention_name>
    <description>100 mg, once daily, 12 months</description>
    <arm_group_label>lamotrigine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  definitive multiple sclerosis according to Mc Donald criteria

          -  clinical isolated syndrome according to Mc Donald criteria

          -  Expanded Disability Status Scale Score 0-5

          -  Pre-treatment with interferon beta 1a (Avonex) since at least 2 months before
             inclusion

        Exclusion Criteria:

          -  relapse within 30 days prior to randomisation

          -  steroid pulse therapy within 30 days prior to randomisation

          -  pregnancy or poor contraception

          -  contraindication for lamotrigine

          -  depressive symptoms

          -  drugs with possible interaction with lamotrigine according to instruction leaflet

          -  other medical relevant conditions but multiple sclerosis

          -  clinically relevant laboratory results

          -  contraindication for MRI

          -  missing informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Norman Putzki, MD</last_name>
    <phone>+4171494</phone>
    <phone_ext>1663</phone_ext>
    <email>norman.putzki@kssg.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ozgur Yaldizli, MD</last_name>
    <phone>+4171494</phone>
    <phone_ext>3587</phone_ext>
    <email>oezguer.yaldizli@kssg.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cantonal Hospital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Putzki, MD</last_name>
      <phone>+4171494</phone>
      <phone_ext>1663</phone_ext>
      <email>norman.putzki@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Norman Putzki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ozgur Yaldizli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <last_update_submitted>June 9, 2009</last_update_submitted>
  <last_update_submitted_qc>June 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Norman Putzki</name_title>
    <organization>Cantonal Hospital of St. Gallen</organization>
  </responsible_party>
  <keyword>neuroprotection</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>brain atrophy</keyword>
  <keyword>mr-spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

